drugset
drugset / Trial / NCT05287308

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

NCT05287308 ↗

Not yet recruiting 500 enrolled Chinese Academy of Medical Sciences CSPC Ouyi Pharmaceutical Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.

Timeline

Start
2022-03
Primary completion
2027-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Docetaxel Small molecule 80 mg/m2 Intravenous
Comparator Docetaxel Small molecule 100 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 80 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 125 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 175 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 260 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 60 mg/m2 Intravenous
Background Epirubicin Small molecule 80 mg/m2 Intravenous
Background Epirubicin Small molecule 100 mg/m2 Intravenous
Background Pirarubicin Small molecule 40 mg/m2 Intravenous
Background Pirarubicin Small molecule 50 mg/m2 Intravenous

Indications

breast cancer